Navigation Links
Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.
Date:12/31/2012

Boulder, Colorado (PRWEB) December 31, 2012

Centagen, Inc. has announced a new discovery that allows for the expansion of a person's own adult stem cells up to a million times without aging. The company believes this will greatly improve treatment for many types of chronic pain, disability and diseases. This might even be a real beginning at reversing the aging process since it supplies the body with a large number of one's own rejuvenated stem cells to rebuild organs and tissues that have been damaged by aging, injury or disease. Even better this type of adult stem cell therapy could be available fairly soon.

Each of us has a limited supply of the kind of stem cells needed to rebuild, repair, and rejuvenate any part of our body. As we age, the supply and healing power of our stem cells diminishes. By providing a practically unlimited supply of one's own rejuvenated stem cells, we may keep people young and healthy for well over a century. In particular, regenerating tissues and organs prepared by expanding one’s own stem cells could help with Alzheimer’s disease, diabetes, immune senescence, damaged heart tissue, arteriosclerosis, failing kidneys, failing hearing or eyesight, osteoporosis, weak muscles, and aged skin.

The technology requires no genetic engineering of the stem cells, so the procedure is much safer than the current procedures requiring genetic tampering. Only a patient’s adult stem cells are used, so there are no ethical issues common with embryonic stem cell use or side effects due to tissue rejection by your immune system.

Centagen has recently opened a crowd funding bid at http://www.indiegogo.com/centagen in concert with Maximum Life foundation, whose mission is to make “100 years old the new 50”.

Forward-Looking Statements for Centagen, Inc.

This press release contains several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy of stem cell therapeutics. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors and the Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control. The Company may not update these forward-looking statements in a timely manner as conditions change.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10281647.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Thackray Crane Rental Prepares Visible Memorial For The Newtown, Connecticut Children and Adults Who Were Ambushed and Taken Away From Their Families
2. Some Bilberry Fruit Extracts Adulterated, says Nonprofit Research Consortium
3. StemGenex to Launch Adult Stem Cell-Based Therapy to Relieve COPD Symptoms
4. NIH media availability: Protein linked to increased risk of heart failure and death in older adults
5. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. Nonprofit Consortium Publishes Review of Skullcap Adulteration
8. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
9. American Botanical Council Publishes a History of Adulteration
10. Epilepsy Foundation and Epilepsy Therapy Project Finalize Merger To Create Strong, Unified Organization To Support People with Epilepsy
11. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 20, 2017 , ... Corporate Directors Forum is recognizing six San Diego directors ... Year Awards. , The awards will be presented Thursday, September 7th, from 6 to ... who have made significantly positive contributions in the boardrooms of some of our region’s ...
(Date:7/18/2017)... Basel, Switzerland (PRWEB) , ... July 18, 2017 ... ... for R&D, today announced that Merck, a leading science and technology company, has ... develop innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... finance technology, DataForm Software ( https://dataformsoftware.com ) announces the migration of its flagship ... Microsoft Azure. Planet is a team-centric, enterprise work management system that merges strategic ...
(Date:7/17/2017)... ... July 17, 2017 , ... OHAUS Corporation, a ... launch of its new line of Heavy-Duty Orbital Shakers today. , Eight New ... digital) for laboratory applications. These shakers are ideal for load capacities from ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):